<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Complete Oseltamivir (Tamiflu) Dosing Information</title>
    <style>
        body {
            font-family: Arial, sans-serif;
            line-height: 1.6;
            max-width: 1000px;
            margin: 0 auto;
            padding: 20px;
            color: #333;
        }
        .pharmacist-credit {
            background-color: #f0f4f8;
            padding: 15px;
            margin-bottom: 20px;
            border-left: 5px solid #3498db;
            text-align: center;
        }
        .pharmacist-name {
            font-size: 1.5em;
            color: #2c3e50;
            font-weight: bold;
            margin-bottom: 10px;
        }
        .pharmacist-title {
            color: #7f8c8d;
            font-style: italic;
        }
        h1 {
            color: #2c3e50;
            border-bottom: 2px solid #3498db;
            padding-bottom: 10px;
        }
        h2 {
            color: #2980b9;
            margin-top: 25px;
        }
        .source {
            background-color: #f8f9fa;
            padding: 15px;
            border-left: 4px solid #3498db;
            margin: 10px 0;
        }
        .quote {
            font-style: italic;
            color: #555;
            margin: 10px 0;
            padding-left: 20px;
            border-left: 3px solid #ddd;
        }
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
        }
        th, td {
            border: 1px solid #ddd;
            padding: 12px;
            text-align: left;
        }
        th {
            background-color: #3498db;
            color: white;
        }
        tr:nth-child(even) {
            background-color: #f2f2f2;
        }
        .important {
            background-color: #e8f4f8;
            padding: 15px;
            border-radius: 5px;
            margin: 20px 0;
        }
        .section {
            margin: 30px 0;
            padding: 20px;
            background-color: #ffffff;
            border-radius: 5px;
            box-shadow: 0 2px 4px rgba(0,0,0,0.1);
        }
    </style>
</head>
<body>
      <div class="pharmacist-credit">
        <div class="pharmacist-name">Mohamed Kamal Telis</div>
        <div class="pharmacist-title">Pharmacist</div>
      </div>
    <h1>Dosing Information for Oseltamivir Suspension (Tamiflu) in Children</h1>
    
    <p>This evidence-based dosing information for oseltamivir suspension (Tamiflu) in children has been prepared by Pharmacist Mohamed Kamal Telis, adhering to specific requirements and evidence-based guidelines.</p>

    <div class="section">
        <h2>Minimum Age</h2>
        <p>Oseltamivir is indicated for the treatment of acute, uncomplicated influenza in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. It is also indicated for the prophylaxis of influenza in patients 1 year and older.</p>
        
        <div class="source">
            <strong>Source:</strong> Tamiflu (oseltamivir phosphate) oral suspension, for suspension [package insert]. South San Francisco, CA: Genentech USA, Inc.; 2023.<br>
            <div class="quote">"TAMIFLU is indicated for the treatment of acute, uncomplicated influenza in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours...TAMIFLU is indicated for prophylaxis of influenza in patients 1 year and older."</div>
        </div>
    </div>

    <div class="section">
        <h2>Treatment Dosing Recommendations (Children 2 weeks to 12 years)</h2>
        <p>Dosing for treatment of influenza in children is based on weight. These recommendations are consistent across the package insert and the CDC guidelines.</p>
        
        <table>
            <thead>
                <tr>
                    <th>Weight Range</th>
                    <th>Dose</th>
                    <th>Frequency</th>
                    <th>Duration</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>≤15 kg</td>
                    <td>30 mg</td>
                    <td>Twice daily</td>
                    <td>5 days</td>
                </tr>
                <tr>
                    <td>>15 kg to ≤23 kg</td>
                    <td>45 mg</td>
                    <td>Twice daily</td>
                    <td>5 days</td>
                </tr>
                <tr>
                    <td>>23 kg to ≤40 kg</td>
                    <td>60 mg</td>
                    <td>Twice daily</td>
                    <td>5 days</td>
                </tr>
                <tr>
                    <td>>40 kg</td>
                    <td>75 mg</td>
                    <td>Twice daily</td>
                    <td>5 days</td>
                </tr>
            </tbody>
        </table>

        <div class="source">
            <strong>Source 1:</strong> Tamiflu (oseltamivir phosphate) oral suspension, for suspension [package insert]. South San Francisco, CA: Genentech USA, Inc.; 2023.<br>
            <div class="quote">"The recommended oral dose of TAMIFLU for treatment of influenza in pediatric patients 2 weeks to 12 years of age is based on body weight. See Table 1." (Table 1 then lists the weight-based dosing above).</div>
        </div>

        <div class="source">
            <strong>Source 2:</strong> Centers for Disease Control and Prevention (CDC). Influenza (Flu). Information for Health Professionals. Antiviral Medications: Summary for Clinicians. Updated September 26, 2023. Accessed November 6, 2023.<br>
            <div class="quote">"Oseltamivir is approved for treatment of influenza in children ≥2 weeks old. For treatment of influenza in children 2 weeks to 12 years old, the recommended oral dose of oseltamivir is based on body weight (see below)."</div>
        </div>
    </div>

    <div class="section">
        <h2>Prophylaxis Dosing Recommendations (Children 1 year to 12 years)</h2>
        <p>Dosing for prophylaxis of influenza in children is also based on weight, and again, the recommendations are consistent between the package insert and CDC guidelines.</p>

        <table>
            <thead>
                <tr>
                    <th>Weight Range</th>
                    <th>Dose</th>
                    <th>Frequency</th>
                    <th>Duration</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>≤15 kg</td>
                    <td>30 mg</td>
                    <td>Once daily</td>
                    <td>10 days</td>
                </tr>
                <tr>
                    <td>>15 kg to ≤23 kg</td>
                    <td>45 mg</td>
                    <td>Once daily</td>
                    <td>10 days</td>
                </tr>
                <tr>
                    <td>>23 kg to ≤40 kg</td>
                    <td>60 mg</td>
                    <td>Once daily</td>
                    <td>10 days</td>
                </tr>
                <tr>
                    <td>>40 kg</td>
                    <td>75 mg</td>
                    <td>Once daily</td>
                    <td>10 days</td>
                </tr>
            </tbody>
        </table>

        <div class="source">
            <strong>Source 1:</strong> Tamiflu (oseltamivir phosphate) oral suspension, for suspension [package insert]. South San Francisco, CA: Genentech USA, Inc.; 2023.<br>
            <div class="quote">"The recommended oral dose of TAMIFLU for prophylaxis of influenza in pediatric patients 1 year to 12 years of age is based on body weight. See Table 2."</div>
        </div>

        <div class="source">
            <strong>Source 2:</strong> Centers for Disease Control and Prevention (CDC). Influenza (Flu). Information for Health Professionals. Antiviral Medications: Summary for Clinicians. Updated September 26, 2023.<br>
            <div class="quote">"Oseltamivir is approved for prophylaxis of influenza in children ≥1 year old. For prophylaxis of influenza in children 1 year to 12 years old, the recommended oral dose of oseltamivir is based on body weight (see below)."</div>
        </div>
    </div>

    <div class="section">
        <h2>Dosing for Adolescents (13 years and older) and Adults</h2>
        <table>
            <thead>
                <tr>
                    <th>Indication</th>
                    <th>Dose</th>
                    <th>Frequency</th>
                    <th>Duration</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Treatment</td>
                    <td>75 mg</td>
                    <td>Twice daily</td>
                    <td>5 days</td>
                </tr>
                <tr>
                    <td>Prophylaxis</td>
                    <td>75 mg</td>
                    <td>Once daily</td>
                    <td>10 days</td>
                </tr>
            </tbody>
        </table>

        <div class="source">
            <strong>Source:</strong> Tamiflu (oseltamivir phosphate) oral suspension, for suspension [package insert]. South San Francisco, CA: Genentech USA, Inc.; 2023.<br>
            <div class="quote">"The recommended oral dose of TAMIFLU for treatment of influenza in adults and adolescents 13 years and older is 75 mg twice daily for 5 days...The recommended dose of TAMIFLU for prophylaxis of influenza in adults and adolescents 13 years and older is 75 mg once daily for at least 10 days."</div>
        </div>
    </div>

    <div class="section">
        <h2>Influenza A/B Strain Differences in Dosing</h2>
        <p>The dosing of oseltamivir <em>does not</em> differ based on whether the influenza infection is caused by influenza A or influenza B. The recommended doses provided above are applicable for both strains. The effectiveness of oseltamivir in treating influenza B may be slightly lower compared to influenza A, but the dosage remains the same.</p>
    </div>

    <div class="section">
        <h2>Discrepancies Between Sources</h2>
        <p>There are no significant discrepancies in the dosing recommendations between the package insert and the CDC guidelines. Both sources are aligned in their recommendations based on age and weight for both treatment and prophylaxis. This consistency reflects the standardized and evidence-based approach to oseltamivir dosing.</p>
    </div>

    <div class="important">
        <h2>Important Considerations</h2>
        <ul>
            <li>Always verify the patient's weight accurately before calculating the dose.</li>
            <li>Oseltamivir is most effective when started within 48 hours of symptom onset.</li>
            <li>Ensure proper reconstitution of the oral suspension according to the manufacturer's instructions.</li>
            <li>Counsel parents/caregivers on proper administration and storage of the medication.</li>
        </ul>
    </div>
</body>
                      </html>
